Maureen K. Highkin

This study shows that HER2 and TP53 co-mutant cancers have increased histone acetylation and are sensitive to neratinib plus trastuzumab deruxtecan.

This paper develops a mouse model of HER2-positive breast cancer cerebellar metastases and identifies IL34-induced Arg1+ macrophages as key drivers of tumor growth, showing that targeting CSF1R can reduce metastases.

The paper tests neratinib combinations with T-DM1 and vinorelbine in HER2 mutated breast cancer PDX models and organoids, finding synergistic effects that could inform clinical trials.